Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Last trade$0.9205
Day change-$0.0496 (-5.11%)
Day range$0.87 – $1.00
Volume75,431
Market cap$51M
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$50.62M
Price / earnings
—
Price / book
0.76×
Price / sales
57.92×
EV / sales
33.36×
EV / EBITDA
-0.88×
Profitability
Earnings per share
-$0.57
Return on assets
-35.68%
Return on equity
-44.69%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
2.35×
Quick ratio
2.32×
Cash ratio
2.01×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$29.99M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RFL, quarterly periods
Line item
Q4 FY2026 Jul 31, 2026
Q3 FY2026 Apr 30, 2026
Q2 FY2026 Jan 31, 2026
Q1 FY2026 Oct 31, 2025
Q4 FY2025 Jul 31, 2025
Q3 FY2025 Apr 30, 2025
Q2 FY2025 Jan 31, 2025
Q1 FY2025 Oct 31, 2024
Revenue
$244K
$179K
$211K
$240K
$350K
$362K
$77K
$128K
Cost of revenue
$13K
$8K
$12K
$9K
$19K
$40K
$38K
$37K
Gross profit
$231K
$171K
$199K
$231K
$331K
$322K
$39K
$91K
Selling, general and administrative
$2.44M
$2.14M
$2.27M
$2.84M
$5.5M
$3.17M
$2.59M
$2.52M
Research and development
$7.47M
$4.85M
$4.53M
$7.48M
$7.55M
$3M
$947K
$1.33M
Total operating expenses
$9.96M
$7.04M
$6.85M
$10.37M
$13.09M
$6.24M
$6.68M
$3.94M
Operating income
-$9.73M
-$6.87M
-$6.66M
-$10.14M
-$12.76M
-$5.91M
-$6.64M
-$3.84M
Interest expense
-$6K
-$6K
-$161K
-$160K
-$168K
-$165K
-$163K
-$162K
Income before taxes
-$9M
-$2.89M
-$6.28M
-$9.79M
-$12.23M
-$6.46M
-$5.31M
-$9.2M
Income taxes
-$65K
$6K
$48K
$10K
-$174K
-$2.41M
$20K
$12K
Net income
-$8.93M
-$2.9M
-$6.33M
-$9.8M
-$12.05M
-$4.05M
-$5.33M
-$9.21M
Net income attributable to common shareholders
-$9.18M
-$4.23M
-$6.42M
-$9.82M
-$12.09M
-$4.78M
-$4.64M
-$9.01M
EBITDA
-$9.68M
-$6.82M
-$6.6M
-$10.09M
-$12.71M
-$5.85M
-$3.5M
-$3.76M
Basic earnings per share
-$0.18
-$0.08
-$0.13
-$0.19
-$0.27
-$0.19
-$0.19
-$0.37
Diluted earnings per share
-$0.18
-$0.08
-$0.13
-$0.19
-$0.27
-$0.19
-$0.19
-$0.37
Recent news
Company coverage with links to the original publishers.
Pomerantz LLP is investigating securities fraud claims on behalf of investors of Rafael Holdings, Inc. after the company announced that its Phase 3 clinical trial for Trappsol Cyclo failed to achieve statistical significance on its primary endpoint. Rafael's stock price fell 34.98% following the announcement on September 30, 2026. The law firm is also investigating similar claims against FMC Corporation and Neogen Corporation.
B.O.S. Better Online Solutions reported strong Q2 2025 results with 36% revenue growth and 53% net income increase, driven primarily by defense sector demand and a robust supply chain division.
Rafael Holdings announced that CEO Bill Conkling will be stepping down, with Executive Chairman Howard Jonas assuming the CEO role. The company is focused on the development of its lead clinical candidate, Trappsol® Cyclo™, for the treatment of Niemann-Pick Disease Type C1.
Rafael Holdings has completed its merger with Cyclo Therapeutics, a biotechnology company focused on developing treatments for Niemann-Pick Disease Type C1. The combined company will focus on advancing Cyclo's lead clinical candidate, Trappsol® Cyclo™, which is currently in a Phase 3 trial for NPC1.
Rafael Holdings reported a net loss for the second quarter and first six months of fiscal year 2025, primarily due to unrealized losses on its investment in Cyclo Therapeutics. The company is focused on Cyclo's lead clinical program Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 following the planned merger with Cyclo Therapeutics.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Dec 18, 2009
$0.0202
Dec 31, 2009
unknown
Jun 19, 2009
$0.0145
Jun 30, 2009
unknown
Mar 20, 2009
$0.0242
Mar 31, 2009
unknown
Dec 19, 2008
$0.1406
Dec 31, 2008
unknown
Stock splits
Historical share-structure events and their execution dates.